Labcorp Holdings Inc. (LH)
NYSE · Healthcare · Diagnostics & Research
$308.65+0.05%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $25.0B
- P/E (trailing)
- 25.5
- Forward P/E
- 15.6
- Dividend yield
- 0.9%
- 52-week range
- $244.52 – $341.80
- 52-week change
- +10.32%
- EPS (trailing)
- $12.10
- Analyst rating
- 1.7 Buy
- Next earnings
- Oct 28, 2026
Fiscal year to Dec 2025
- Revenue
- $14.0B (+7.25%)
- Net income
- $877M
- Operating margin
- 9.9%
- Diluted EPS
- $10.46
- Free cash flow
- $1.2B
From the company’s annual report on SEC EDGAR.
About Labcorp Holdings Inc.
Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing service, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations.
Headquarters: Burlington, United States · 71,000 employees · labcorp.com